PowderJect to start vaccine trial
PowderJect is to start clinical trials of a vaccine to combat hepatitis B as part of its continuing strategic alliance with GlaxoSmithKline.
Oxford-based PowderJect, through its subsidiary PowderJect Vaccines, will study the effectiveness of a DNA immunotherapeutic treatment to combat hepatitis B, the chronic viral infection.